Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 0.50%, near the low end of its 5-year range (0.00%–4.95%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 0.01%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
0.01%
DEBT TO ASSETS RATIO AVG 3Y
1.60%
DEBT TO ASSETS RATIO AVG 5Y
0.50%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 536 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$266.71M
Debt to Assets Ratio
0.00%
TTM Avg
0.01%
3Y Avg
1.60%
5Y Avg
0.50%
Market Cap
$266.18M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.23M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.26M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.64M
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.47M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$277.81M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.84M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $266.71M | 0.00% | 0.01% | 1.60% | 0.50% |
| Century Therapeutics, Inc. (IPSC)vs › | $266.18M | 0.12% | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.23M | 0.03% | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.26M | 0.10% | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $261.64M | 0.13% | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.47M | 0.01% | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $274.28M | 0.03% | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $277.81M | 0.04% | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $280.84M | 0.00% | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | 0.02% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
15.82
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.04% |
| 2025-03-31 | 0.08% |
| 2024-12-31 | 0.11% |
| 2024-09-30 | 4.95% |
| 2024-06-30 | 4.02% |
| 2024-03-31 | 4.43% |
| 2023-12-31 | 4.29% |
| 2023-09-30 | 1.51% |
| 2023-06-30 | 1.33% |
| 2023-03-31 | 1.15% |
| 2022-12-31 | 1.41% |
| 2022-09-30 | 1.31% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.59% |
| 2021-09-30 | 0.54% |
| 2021-06-30 | 0.51% |
| 2021-03-31 | 10.47% |
| 2020-12-31 | 2.16% |
| 2020-09-30 | 49.00% |
| 2020-06-30 | 182.57% |
| 2020-03-31 | 1743.48% |
| 2019-12-31 | 977.14% |
| 2018-12-31 | 8.21% |
| 2018-03-31 | 147.91% |
| 2017-12-31 | 161.30% |
